A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants
Status:
Completed
Trial end date:
2019-08-25
Target enrollment:
Participant gender:
Summary
This is a Phase 1, randomized, blinded, placebo-controlled study in up to approximately 51
non-diabetic obese participants with a body mass index (BMI) ≥ 35 kg/m^2. The participants
will be observed among 3 separate cohorts and participate in the study for up to
approximately 27 weeks, including a screening period (including a run-in), treatment period,
and safety follow-up.